Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.
Conclusion: Our data indicate that generic imatinib does not have deleterious effects on CML control and present an acceptable safety profile, similar or better than brand imatinib.
PMID: 32792470 [PubMed - as supplied by publisher]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Italy Health | Leukemia | Study